Literature DB >> 9931111

Genomics and hypertension: concepts, potentials, and opportunities.

R E Pratt1, V J Dzau.   

Abstract

We are at the beginning of a biological revolution, spurred on by the Human Genome Project and associated studies. Within the next few years, expressed sequence tags (ESTs) representing all sequences expressed in humans will be determined and their genomic positions will be defined (STSs). The discovery of all the variants in the human genome that contribute to the genetic diversity of the human population will result in the construction of dense polymorphic maps. The rapid growth of the EST, STS, and single-nucleotide polymorphism (SNP) databases, coupled with impressive technological advances, will surely have a dramatic effect on biomedical research. In this review, we will examine the recent advances in genetics and genomics and place these within the context of medical research and patient care, with an emphasis on studies in the cardiovascular system.

Entities:  

Mesh:

Year:  1999        PMID: 9931111     DOI: 10.1161/01.hyp.33.1.238

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  10 in total

1.  Matters of the heart transcriptome: a brief history of cardiovascular genomics.

Authors:  Pilar M Labordé-Lahoz
Journal:  Tex Heart Inst J       Date:  2002

2.  Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension.

Authors:  V R Holla; F Adas; J D Imig; X Zhao; E Price; N Olsen; W J Kovacs; M A Magnuson; D S Keeney; M D Breyer; J R Falck; M R Waterman; J H Capdevila
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

Review 3.  Genomics and the pathophysiology of heart failure.

Authors:  J J Hwang; V J Dzau; C C Liew
Journal:  Curr Cardiol Rep       Date:  2001-05       Impact factor: 2.931

Review 4.  The genomics of cardiovascular disorders: therapeutic implications.

Authors:  P Ferrari; G Bianchi
Journal:  Drugs       Date:  2000-05       Impact factor: 9.546

5.  The association of -627 interleukin-10 promoter polymorphism in Chinese patients with systemic lupus erythematosus.

Authors:  Po-Wen Lin; Chung-Ming Huang; Chiu-Ching Huang; Chang-Hai Tsai; Jeffrey J P Tsai; Chin-Ping Chang; Fuu-Jen Tsai
Journal:  Clin Rheumatol       Date:  2006-07-07       Impact factor: 2.980

6.  Relation of polymorphism in the promotor region for the human osteocalcin gene to bone mineral density and occurrence of osteoporosis in postmenopausal Chinese women in Taiwan.

Authors:  H Y Chen; H D Tsai; W C Chen; J Y Wu; F J Tsai; C H Tsai
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

Review 7.  Gene therapy of hypertensive vascular injury.

Authors:  Y Chu; F M Faraci; D D Heistad
Journal:  Curr Hypertens Rep       Date:  2000-02       Impact factor: 5.369

8.  A common polymorphism associated with antibiotic-induced cardiac arrhythmia.

Authors:  F Sesti; G W Abbott; J Wei; K T Murray; S Saksena; P J Schwartz; S G Priori; D M Roden; A L George; S A Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

Review 9.  Hypertension genomics and cardiovascular prevention.

Authors:  Fu Liang Ng; Helen R Warren; Mark J Caulfield
Journal:  Ann Transl Med       Date:  2018-08

10.  p38/JNK Is Required for the Proliferation and Phenotype Changes of Vascular Smooth Muscle Cells Induced by L3MBTL4 in Essential Hypertension.

Authors:  Chaowei Hu; Kun Zuo; Kuibao Li; Yuanfeng Gao; Mulei Chen; Roumu Hu; Ye Liu; Hongjie Chi; Hongjiang Wang; Yanwen Qin; Xiaoyan Liu; Jiuchang Zhong; Jun Cai; Xinchun Yang; Jing Li
Journal:  Int J Hypertens       Date:  2020-12-16       Impact factor: 2.420

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.